AAP: Choosing Wisely Recs on Pediatric Pulmonology, Sleep Medicine
The list, titled “Five Things Physicians and Patients Should Question,” was developed by members of the AAP Section on Pediatric Pulmonology and Sleep Medicine.
Diagnosis & Disease Information
CPAP Therapy for 6 Months in OSA May Reverse Metabolic Syndrome
Continuous positive airway pressure therapy for 6 months offers patients with obstructive sleep apnea a greater chance of reversing metabolic syndrome.
Specificities and Sensitivities of OSA Screening Tools for People With HIV
In terms of screening for obstructive sleep apnea in people living with HIV, the STOP-BANG questionnaire had good sensitivity, whereas the Berlin questionnaire and the Epworth Sleepiness Scale demonstrated good specificity.
Pitolisant Add-On CPAP Therapy Reduces Excessive Daytime Sleepiness in OSA
Pitolisant may be used as an add-on therapy to continuous positive airway pressure in patients with obstructive sleep apnea suffering from residual diurnal somnolence.
Inspire Therapy Approved for Younger Patients With Obstructive Sleep Apnea
The Food and Drug Administration (FDA) has expanded the approval of Inspire therapy (Inspire Medical Systems) to include patients aged 18 to 21 years with moderate to severe obstructive sleep apnea (OSA) who are unable to use continuous positive airway pressure (CPAP). Previously, the therapy was only approved for patients 22 years of age and…
Guidelines Issued for Insomnia, Sleep Apnea in Current, Former Soldiers
VA and DoD joint guideline addresses sleep disorders in military personnel and veterans.
New Drug Product: Sunosi
This slideshow reviews drug information for Sunosi. Click here for the complete Sunosi monograph.
Sunosi Approved for Excessive Daytime Sleepiness With Narcolepsy, OSA
Jazz Pharmaceuticals announced that the Food and Drug Administration (FDA) has approved Sunosi (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.
FDA Accepts Solriamfetol NDA for Narcolepsy-, OSA-Related Sleepiness
Solriamfetol is a selective dopamine and norepinephrine reuptake inhibitor.
